Your browser doesn't support javascript.
loading
Left-Sided Degenerative Valvular Heart Disease in Type 1 and Type 2 Diabetes.
Rawshani, Araz; Sattar, Naveed; McGuire, Darren K; Wallström, Oskar; Smith, Ulf; Borén, Jan; Bergström, Göran; Omerovic, Elmir; Rosengren, Annika; Eliasson, Björn; Bhatt, Deepak L; Rawshani, Aidin.
Afiliação
  • Rawshani A; Department of Molecular and Clinical Medicine (Araz Rawshani, O.W., U.S., J.B., G.B., E.O., A. Rosengren, Aidin Rawshani), University of Gothenburg, Sweden.
  • Sattar N; Wallenberg Laboratory for Cardiovascular and Metabolic Research (Araz Rawshani, U.S., J.B., G.B., E.O., A. Rosengren, Aidin Rawshani), University of Gothenburg, Sweden.
  • McGuire DK; Institute of Cardiovascular and Medical Sciences, British Heart Foundation Glasgow Cardiovascular Research Centre, Glasgow, United Kingdom (N.S.).
  • Wallström O; Department of Internal Medicine, University of Texas Southwestern Medical Center, and Parkland Health and Hospital System, Dallas (D.K.M.).
  • Smith U; Department of Molecular and Clinical Medicine (Araz Rawshani, O.W., U.S., J.B., G.B., E.O., A. Rosengren, Aidin Rawshani), University of Gothenburg, Sweden.
  • Borén J; Department of Molecular and Clinical Medicine (Araz Rawshani, O.W., U.S., J.B., G.B., E.O., A. Rosengren, Aidin Rawshani), University of Gothenburg, Sweden.
  • Bergström G; Wallenberg Laboratory for Cardiovascular and Metabolic Research (Araz Rawshani, U.S., J.B., G.B., E.O., A. Rosengren, Aidin Rawshani), University of Gothenburg, Sweden.
  • Omerovic E; Institute of Medicine, The Lundberg Laboratory for Diabetes Research, Department of Molecular and Clinical Medicine (U.S., B.E., Aidin Rawshani), University of Gothenburg, Sweden.
  • Rosengren A; Department of Molecular and Clinical Medicine (Araz Rawshani, O.W., U.S., J.B., G.B., E.O., A. Rosengren, Aidin Rawshani), University of Gothenburg, Sweden.
  • Eliasson B; Wallenberg Laboratory for Cardiovascular and Metabolic Research (Araz Rawshani, U.S., J.B., G.B., E.O., A. Rosengren, Aidin Rawshani), University of Gothenburg, Sweden.
  • Bhatt DL; Wallenberg Laboratory for Cardiovascular and Metabolic Research (Araz Rawshani, U.S., J.B., G.B., E.O., A. Rosengren, Aidin Rawshani), University of Gothenburg, Sweden.
  • Rawshani A; Department of Clinical Physiology, Sahlgrenska University Hospital, Region Västra Götaland, Gothenburg, Sweden (G.B., Aidin Rawshani).
Circulation ; 146(5): 398-411, 2022 08 02.
Article em En | MEDLINE | ID: mdl-35678729
ABSTRACT

BACKGROUND:

The role of diabetes in the development of valvular heart disease, and, in particular, the relation with risk factor control, has not been extensively studied.

METHODS:

We included 715 143 patients with diabetes registered in the Swedish National Diabetes Register and compared them with 2 732 333 matched controls randomly selected from the general population. First, trends were analyzed with incidence rates and Cox regression, which was also used to assess diabetes as a risk factor compared with controls, and, second, separately in patients with diabetes according to the presence of 5 risk factors.

RESULTS:

The incidence of valvular outcomes is increasing among patients with diabetes and the general population. In type 2 diabetes, systolic blood pressure, body mass index, and renal function were associated with valvular lesions. Hazard ratios for patients with type 2 diabetes who had nearly all risk factors within target ranges, compared with controls, were as follows aortic stenosis 1.34 (95% CI, 1.31-1.38), aortic regurgitation 0.67 (95% CI, 0.64-0.70), mitral stenosis 1.95 (95% CI, 1.76-2.20), and mitral regurgitation 0.82 (95% CI, 0.79-0.85). Hazard ratios for patients with type 1 diabetes and nearly optimal risk factor control were as follows aortic stenosis 2.01 (95% CI, 1.58-2.56), aortic regurgitation 0.63 (95% CI, 0.43-0.94), and mitral stenosis 3.47 (95% CI, 1.37-8.84). Excess risk in patients with type 2 diabetes for stenotic lesions showed hazard ratios for aortic stenosis 1.62 (95% CI, 1.59-1.65), mitral stenosis 2.28 (95% CI, 2.08-2.50), and excess risk in patients with type 1 diabetes showed hazard ratios of 2.59 (95% CI, 2.21-3.05) and 11.43 (95% CI, 6.18-21.15), respectively. Risk for aortic and mitral regurgitation was lower in type 2 diabetes 0.81 (95% CI, 0.78-0.84) and 0.95 (95% CI, 0.92-0.98), respectively.

CONCLUSIONS:

Individuals with type 1 and 2 diabetes have greater risk for stenotic lesions, whereas risk for valvular regurgitation was lower in patients with type 2 diabetes. Patients with well-controlled cardiovascular risk factors continued to display higher risk for valvular stenosis, without a clear stepwise decrease in risk between various degrees of risk factor control.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Insuficiência da Valva Aórtica / Estenose da Valva Aórtica / Diabetes Mellitus Tipo 1 / Diabetes Mellitus Tipo 2 / Doenças das Valvas Cardíacas / Insuficiência da Valva Mitral / Estenose da Valva Mitral Tipo de estudo: Diagnostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Circulation Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Suécia

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Insuficiência da Valva Aórtica / Estenose da Valva Aórtica / Diabetes Mellitus Tipo 1 / Diabetes Mellitus Tipo 2 / Doenças das Valvas Cardíacas / Insuficiência da Valva Mitral / Estenose da Valva Mitral Tipo de estudo: Diagnostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Circulation Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Suécia